— Oncoclinicas signed a non-binding agreement with insurer Porto Seguro to create a new oncology company, with Porto investing R$500 million ($94 million) for at least 30% of the new entity
— The new company would also issue R$500 million ($94 million) in convertible debentures subscribed by Porto, bringing the potential total commitment to R$1 billion ($188 million)
— CFO Camille Loyo Faria resigned the same day, replaced by board member Marcel Cecchi Vieira, adding leadership upheaval to an already complex restructuring
Brazilian oncology group Oncoclinicas announced Sunday evening that it signed a non-binding term sheet with insurer Porto Seguro to create a new company dedicated to cancer treatment services, in what amounts to a strategic restructuring of one of Latin America’s largest oncology networks. The Oncoclinicas Porto Seguro deal would see the insurer invest R$500 million ($94 million) in the new entity while Oncoclinicas contributes its clinic operations, according to a filing with Brazil’s securities regulator CVM. The Rio Times, the Latin American financial news outlet, covers Brazil financial news English and the corporate developments reshaping the country’s healthcare sector.
Oncoclinicas Porto Seguro Deal Structure
Under the proposed terms, the new company — referred to as NewCo — would consolidate Oncoclinicas’ roughly 200 oncology clinic assets and operations, while non-clinic assets such as the group’s hospital operations would remain with the parent company. Porto Seguro would subscribe to ordinary shares giving it voting control and a minimum 30% stake in the total share capital. Oncoclinicas has committed to negotiate exclusively with Porto for 30 days.
Beyond the initial equity investment, the NewCo would issue R$500 million ($94 million) in convertible debentures with a 48-month maturity, paying 110% of Brazil’s interbank CDI rate. Porto would subscribe to these instruments, with voluntary conversion windows opening from the third anniversary. A portion of Oncoclinicas’ existing debt would also be transferred to the new entity, easing the parent company’s balance sheet. The total potential commitment from Porto Seguro reaches R$1 billion ($188 million), signaling the insurer’s serious ambition in the healthcare vertical.
Board Dissent and CFO Exit
The deal was not unanimously approved. Board members Marcos Grodezky and Raul Rosenthal Ladeira de Matos voted against signing the agreement with Porto Seguro, though the company did not disclose their specific objections. The disclosure itself was complicated by timing: Porto Seguro issued a statement Saturday denying any binding agreement existed, responding to a report by Brazil Journal that broke the story prematurely. Oncoclinicas clarified Sunday that the term sheet is preliminary and non-binding, and that a material fact filing had not been deemed necessary at the time of signing.
In a separate announcement the same evening, Oncoclinicas disclosed that Camille Loyo Faria had resigned as executive vice-president, chief financial officer, and investor relations director. The board elected Marcel Cecchi Vieira, currently a board member, to replace her on an interim basis. The CFO departure adds leadership turbulence at a critical juncture, as the company navigates creditor negotiations and the financial pressure that has weighed on ONCO3 shares throughout 2026.
What the Deal Means for Brazil’s Healthcare Sector
The stock jumped more than 10% on Monday morning in São Paulo following the Oncoclinicas Porto Seguro deal announcement, suggesting investors view the partnership as a potential lifeline for the embattled oncology group. Oncoclinicas is the largest cancer treatment network in Latin America, operating across chemotherapy, radiotherapy, diagnostics, and advanced therapies through partnerships with hospitals and health plan operators. The deal with Porto Seguro — one of Brazil’s biggest insurers — represents a convergence of insurance capital and healthcare delivery that has become an increasingly common theme across the Brazilian market.
Completion of the transaction remains subject to multiple conditions, including due diligence by Porto, regulatory approvals from competition authorities and sector regulators, and internal board and potentially shareholder approvals from both parties. The non-binding nature of the term sheet means no obligations to close exist at this stage, and the 30-day exclusivity window will test whether the parties can convert preliminary terms into definitive agreements while Oncoclinicas simultaneously manages its debt restructuring.